ADRB3 and myeloid leukemia: To better discriminate the role played by β3-AR, we treated three different myeloid leukemia cell lines (HEL, HL60, K562) with another β3-adrenoceptor antagonist, L748,337, and with non-selective β1/β2-AR antagonist propranolol.